The Medicines and Healthcare products Regulatory Agency (MHRA) is formalising its review process around in vitro diagnostics ...
SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in CNS ...
Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...
Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.
William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.
Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.
A spokesperson for the US Department of State told Pharmaceutical Technology that the “American people have paid more than enough” to the WHO.
AFTX-201 uses Affinia’s engineered capsid for efficient cardiac delivery at doses lower than conventional AAV9 or AAVrh74. Credit: Komsan Loonprom / Shutterstock.com. Affinia Therapeutics has received ...
The Navigator collates public materials from authorities such as the FDA alongside industry resources and best practices. Credit: PeopleImages / Shutterstock.com. The Digital Health Measurement ...
In Phase Ib, BSI-082 will be combined with trastuzumab deruxtecan for HER2-positive solid tumours. Credit: PeopleImages / Shutterstock.com. Biosion has dosed the first patient in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results